IL106785A - Use of nadh and nadph as drugs for treating alzheimer's disease - Google Patents

Use of nadh and nadph as drugs for treating alzheimer's disease

Info

Publication number
IL106785A
IL106785A IL106785A IL10678593A IL106785A IL 106785 A IL106785 A IL 106785A IL 106785 A IL106785 A IL 106785A IL 10678593 A IL10678593 A IL 10678593A IL 106785 A IL106785 A IL 106785A
Authority
IL
Israel
Prior art keywords
nadh
nadph
disease
drugs
treating alzheimer
Prior art date
Application number
IL106785A
Other languages
English (en)
Other versions
IL106785A0 (en
Original Assignee
Birkmayer Joerg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Birkmayer Joerg filed Critical Birkmayer Joerg
Publication of IL106785A0 publication Critical patent/IL106785A0/xx
Publication of IL106785A publication Critical patent/IL106785A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IL106785A 1992-09-30 1993-08-24 Use of nadh and nadph as drugs for treating alzheimer's disease IL106785A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4232899A DE4232899C2 (de) 1992-09-30 1992-09-30 Verwendung von NADH und NADPH zur Behandlung von Morbus Alzheimer

Publications (2)

Publication Number Publication Date
IL106785A0 IL106785A0 (en) 1993-12-08
IL106785A true IL106785A (en) 1997-09-30

Family

ID=6469304

Family Applications (1)

Application Number Title Priority Date Filing Date
IL106785A IL106785A (en) 1992-09-30 1993-08-24 Use of nadh and nadph as drugs for treating alzheimer's disease

Country Status (16)

Country Link
US (1) US5444053A (fr)
EP (1) EP0590321B1 (fr)
JP (1) JP3384847B2 (fr)
CN (1) CN1053341C (fr)
AT (1) ATE162076T1 (fr)
AU (1) AU664768B2 (fr)
CA (1) CA2105912C (fr)
DE (2) DE4232899C2 (fr)
DK (1) DK0590321T3 (fr)
ES (1) ES2111104T3 (fr)
GR (1) GR3026120T3 (fr)
IL (1) IL106785A (fr)
MX (1) MX9306049A (fr)
NO (1) NO303482B1 (fr)
TW (1) TW231268B (fr)
ZA (1) ZA936327B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US5668114A (en) * 1996-05-08 1997-09-16 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating hypertension
CA2369231C (fr) * 2000-04-28 2007-04-17 Mizuno Corporation Structure de serrage pour chaussures
ES2314056T3 (es) * 2001-05-02 2009-03-16 Blanchette Rockefeller Neurosciences Institute Activadores de la anhidrasa carbonica para mejorar el aprendizaje y la memoria.
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
DE10254995B4 (de) * 2002-11-26 2005-02-10 Juelich Enzyme Products Gmbh Verfahren zur enzymatischen Reduktion von NAD und NADP
WO2004050099A1 (fr) * 2002-12-03 2004-06-17 Kyowa Hakko Kogyo Co., Ltd. Procede de stabilisation de nicotinamide-adenine-dinucleotide reduit ou de nicotinamide-adenine-dinucleotide-phosphate reduit
US20040126751A1 (en) * 2002-12-27 2004-07-01 Birkmayer Jorg G.D. Method of prolonging the life-span of living cells using NADH, NADPH and ADP-ribose
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
TW200538181A (en) 2004-05-18 2005-12-01 Brni Neurosciences Inst Treatment of depressive disorders
WO2013009997A1 (fr) * 2011-07-12 2013-01-17 Burn-Off, Llc Composition et procédé d'utilisation de la composition, efficace pour minimiser les effets nocifs associés aux individus souffrant d'une intoxication alcoolique
EP2574339A1 (fr) 2011-09-27 2013-04-03 Johannes Huber Préparation pharmaceutique pour le traitement de maladies conditionnées par NADH
CN103340890B (zh) * 2013-06-08 2016-04-27 苏州人本药业有限公司 Nadph作为制备用于防治脑缺血性中风药物方面的应用
CN109562120B (zh) * 2017-08-11 2021-03-19 邦泰生物工程(深圳)有限公司 一种含有nadh和nadph的组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814339A (en) * 1986-02-11 1989-03-21 Advanced Biologics, Inc. Treatment for Alzheimer's disease
JP2736103B2 (ja) * 1988-03-01 1998-04-02 ヴァルター・ビルクマイヤー パーキンソン症候群の治療用医薬、およびその製造方法
AT397200B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung von selenmethionin zur herstellung eines arzneimittels
AT397201B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung des enzym-cofaktors nadph zur herstellung eines arzneimittels

Also Published As

Publication number Publication date
NO933321D0 (no) 1993-09-17
ATE162076T1 (de) 1998-01-15
DK0590321T3 (da) 1998-09-14
DE59307982D1 (de) 1998-02-19
JP3384847B2 (ja) 2003-03-10
MX9306049A (es) 1994-05-31
TW231268B (fr) 1994-10-01
EP0590321B1 (fr) 1998-01-14
CA2105912C (fr) 2000-11-14
JPH06192106A (ja) 1994-07-12
NO933321L (no) 1994-04-05
ZA936327B (en) 1994-03-22
DE4232899C2 (de) 1995-02-23
CN1053341C (zh) 2000-06-14
CA2105912A1 (fr) 1994-03-31
DE4232899A1 (de) 1994-03-31
ES2111104T3 (es) 1998-03-01
IL106785A0 (en) 1993-12-08
EP0590321A1 (fr) 1994-04-06
GR3026120T3 (en) 1998-05-29
AU664768B2 (en) 1995-11-30
AU4488793A (en) 1994-04-14
US5444053A (en) 1995-08-22
CN1089474A (zh) 1994-07-20
NO303482B1 (no) 1998-07-20

Similar Documents

Publication Publication Date Title
PH23867A (en) Method of treating parkinson's disease using indolone derivatives
IL106785A0 (en) Use of nadh and nadph as drugs for treating alzheimer's disease
AU1412088A (en) Therapeutic nucleosides
EP1006793A4 (fr) Compositions pour traiter l'arythmie et procedes de traitement
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
AU3401093A (en) Therapeutic agent for threatened abortion
HU9200025D0 (en) Medical preparations for treating depression
HUT61895A (en) Process for producing pharmaceutical composition against cancer and aids
GR3037039T3 (en) Use of trimetazidine for the preparation of medicaments for the treatment of troubles due to the therapeutical use of immunosuppressants.
EP0457336A3 (en) Use of mizoribine for the treatment or prevention of multiple sclerosis

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees